PUBLISHER: Allied Market Research | PRODUCT CODE: 1192995
PUBLISHER: Allied Market Research | PRODUCT CODE: 1192995
The global coagulation testing market size is envisioned to garner $8,777.3 million by 2031, growing from $3,101.7 million in 2021 at a CAGR of 11.5% from 2022 to 2031.
Medical professionals use coagulation tests to evaluate the hemostasis system. A coagulometer, which monitors and assesses the rate of clot formation or blood coagulation, is mostly used to conduct this test. These examinations reduce the risk of heart attack, thrombosis, and embolism by detecting the presence of blood clots in blood arteries.
Hemostasis (coagulation), a complicated process that regulates blood flow and clot formation, is controlled by numerous enzymes and proteins.
The market is expanding as a result of ongoing technological developments in coagulation testing equipment. The key growth reasons for the coagulation testing market are the rising prevalence of different blood clotting disorders, including deep vein thrombosis (DVT) and haemophilia, as well as the global ageing population. The market is comprehensively evaluated in the study on the global coagulation testing market growth.
Due to stringent government regulations along with high risk and costs associated with tests and treatment which limits its usage to only the population which is economically capable gives a negative impact on the global coagulation testing markets.
In the self-testing technology, the smartphone-based blood coagulation testing device which is driving the growth of the market helps to monitors the blood flow in patients by undergoing an anticoagulant therapy. These factors drives the coagulation testing market demand.
The COVID-19 pandemic brought about a number of difficulties that resulted in significant economic losses as a result of the global shutdown of many firms. There were established import-export limitations. The COVID-19 pandemic has had a beneficial impact on the market for coagulation testing worldwide. Numerous government agencies are taking a number of actions to help businesses survive the coronavirus epidemic. Many government agencies are taking a number of actions to help businesses survive the coronavirus outbreak.
The key players profiled in this report include Thermo Fisher Scientific Inc., Helena Laboratories Corporation., Micropoint Biosciences, Medtronic, F. Hoffmann-La Roche Ltd, NIHON KOHDEN CORPORATION., Abbott., Sysmex Corporation, BD Biosciences., and Danaher.
Key Benefits For Stakeholders
By Product
By Application
By End User
By Region